In this 5th edition, we detail the market size, segmentation, growth and trends of the MDx industry from 2008 to 2016. The 5th edition contains the following updates:

• 2012 actual financials incorporated: Company revenue / growth forecasts have been updated to include actual reported 2012 financials for major market players (e.g., Abbott, BD, Cepheid, Dako, Gen-Probe, Novartis, Qiagen, Roche [including Ventana], Siemens) and minor market players (e.g., GenMark, Life Technologies, Luminex, Meridian). We also incorporated recent 2013 10-Qs (Q1, Q2, Q3) when available.
• Retooled financial model: A brand new model tracking estimated revenues for >250 MDx tests offered by >50 companies

Market growth by segment extended to 2016: For each of the 28 segments assessed in this report, we provide growth estimates through 2016 (extended from 2015 in the 4th edition). The market is segmented by:

• 4 therapeutic areas: Infectious diseases, HPV, oncology, others
• 9 technologies: PCR, qPCR, TMA, hybrid capture, ISH, Arrays, CE Sequencing, NGS sequencing, other [e.g., NASBA]
• 3 plex levels: 1 analyte (e.g., C.diff testing), 2-5 analytes (e.g., HIV 1/2 genotyping), >5 analytes per sample (e.g., HPV genotyping)
• 4 test rationales (screening [including predisposition], diagnosis, therapy selection, monitoring)
• 4 customer types: Hospitals, reference labs, public health laboratories (PHL), blood banks
• 4 geographies: U.S., Europe, Japan, rest of the world [RoW]
• Profiles of emerging companies: This 5th edition cites a number of emerging companies that innovate in specific MDx niches of the market (e.g., point-of-care, emerging technologies)
• Extended content: The new edition contains 20 additional pages, including color and granularity to help understand key products in each category
• Additional expert feedback: This report includes feedback from 15 additional experts

---

Authors: Stephane Budel, Partner at DeciBio, LLCConnect with Stephane Budel on Google+https://plus.google.com/+StephaneBudel